Advertisement
Screener

SpyGlass Pharma, Inc. (SGP) Increase (Decrease) in Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

SpyGlass Pharma, Inc. Increase (Decrease) in Accrued Liabilities

SpyGlass Pharma, Inc. (SGP) reported Increase (Decrease) in Accrued Liabilities of $1.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-03-26

  • SpyGlass Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $1.67M, a 403.61% increase from fiscal 2024.
  • SpyGlass Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $332.00K.
Period endIncrease (Decrease) in Accrued Liabilities 12 month
2025-12-31$1.67M
10-K · filed 2026-03-26
2024-12-31$332.00K
10-K · filed 2026-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beta Bionics, Inc. (BBNX)United States$0.979B-9.66
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77
SI-BONE, Inc. (SIBN)United States$0.830B-49.82
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
IRADIMED CORP (IRMD)United States$1.089B52.92
ARTIVION, INC. (AORT)United States$1.123B-345.09
MIMEDX GROUP, INC. (MDXG)United States$0.687B89.92
ANGIODYNAMICS INC (ANGO)United States$0.632B-13.02
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
ORTHOPEDIATRICS CORP (KIDS)United States$0.592B